Comparison of cilostazol and clopidogrel after successful coronary stenting

Seung Whan Lee, Seong Wook Park, Myeongki Hong, Cheol Whan Lee, Young Hak Kim, Jae Hyeong Park, Su Jin Kang, Ki Hoon Han, Jae Joong Kim, Seung Jung Park

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

This study compared the safety and efficacy of cilostazol and clopidogrel after coronary stenting. Patients (n = 689) who underwent successful stenting were randomly assigned to receive cilostazol (group 1, n = 344, 612 lesions) or clopidogrel (group 2, n = 345, 628 lesions). The incidence of subacute stent thrombosis or major adverse cardiac events, including death, myocardial infarction, and target lesion revascularization within 30 days (2.6% in group 1 vs 2.0% in group 2, p = 0.61) and side effects that required cessation of study drug (0.6% each) did not differ statistically between groups. These results indicate that cilostazol is as safe and effective as clopidogrel in preventing thrombotic complications after stenting.

Original languageEnglish
Pages (from-to)859-862
Number of pages4
JournalAmerican Journal of Cardiology
Volume95
Issue number7
DOIs
Publication statusPublished - 2005 Apr 1

Fingerprint

clopidogrel
Stents
Thrombosis
Myocardial Infarction
Safety
Incidence
Pharmaceutical Preparations
cilostazol

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Lee, Seung Whan ; Park, Seong Wook ; Hong, Myeongki ; Lee, Cheol Whan ; Kim, Young Hak ; Park, Jae Hyeong ; Kang, Su Jin ; Han, Ki Hoon ; Kim, Jae Joong ; Park, Seung Jung. / Comparison of cilostazol and clopidogrel after successful coronary stenting. In: American Journal of Cardiology. 2005 ; Vol. 95, No. 7. pp. 859-862.
@article{fee23464925d487e96dec49f6090f6d4,
title = "Comparison of cilostazol and clopidogrel after successful coronary stenting",
abstract = "This study compared the safety and efficacy of cilostazol and clopidogrel after coronary stenting. Patients (n = 689) who underwent successful stenting were randomly assigned to receive cilostazol (group 1, n = 344, 612 lesions) or clopidogrel (group 2, n = 345, 628 lesions). The incidence of subacute stent thrombosis or major adverse cardiac events, including death, myocardial infarction, and target lesion revascularization within 30 days (2.6{\%} in group 1 vs 2.0{\%} in group 2, p = 0.61) and side effects that required cessation of study drug (0.6{\%} each) did not differ statistically between groups. These results indicate that cilostazol is as safe and effective as clopidogrel in preventing thrombotic complications after stenting.",
author = "Lee, {Seung Whan} and Park, {Seong Wook} and Myeongki Hong and Lee, {Cheol Whan} and Kim, {Young Hak} and Park, {Jae Hyeong} and Kang, {Su Jin} and Han, {Ki Hoon} and Kim, {Jae Joong} and Park, {Seung Jung}",
year = "2005",
month = "4",
day = "1",
doi = "10.1016/j.amjcard.2004.12.012",
language = "English",
volume = "95",
pages = "859--862",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "7",

}

Lee, SW, Park, SW, Hong, M, Lee, CW, Kim, YH, Park, JH, Kang, SJ, Han, KH, Kim, JJ & Park, SJ 2005, 'Comparison of cilostazol and clopidogrel after successful coronary stenting', American Journal of Cardiology, vol. 95, no. 7, pp. 859-862. https://doi.org/10.1016/j.amjcard.2004.12.012

Comparison of cilostazol and clopidogrel after successful coronary stenting. / Lee, Seung Whan; Park, Seong Wook; Hong, Myeongki; Lee, Cheol Whan; Kim, Young Hak; Park, Jae Hyeong; Kang, Su Jin; Han, Ki Hoon; Kim, Jae Joong; Park, Seung Jung.

In: American Journal of Cardiology, Vol. 95, No. 7, 01.04.2005, p. 859-862.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison of cilostazol and clopidogrel after successful coronary stenting

AU - Lee, Seung Whan

AU - Park, Seong Wook

AU - Hong, Myeongki

AU - Lee, Cheol Whan

AU - Kim, Young Hak

AU - Park, Jae Hyeong

AU - Kang, Su Jin

AU - Han, Ki Hoon

AU - Kim, Jae Joong

AU - Park, Seung Jung

PY - 2005/4/1

Y1 - 2005/4/1

N2 - This study compared the safety and efficacy of cilostazol and clopidogrel after coronary stenting. Patients (n = 689) who underwent successful stenting were randomly assigned to receive cilostazol (group 1, n = 344, 612 lesions) or clopidogrel (group 2, n = 345, 628 lesions). The incidence of subacute stent thrombosis or major adverse cardiac events, including death, myocardial infarction, and target lesion revascularization within 30 days (2.6% in group 1 vs 2.0% in group 2, p = 0.61) and side effects that required cessation of study drug (0.6% each) did not differ statistically between groups. These results indicate that cilostazol is as safe and effective as clopidogrel in preventing thrombotic complications after stenting.

AB - This study compared the safety and efficacy of cilostazol and clopidogrel after coronary stenting. Patients (n = 689) who underwent successful stenting were randomly assigned to receive cilostazol (group 1, n = 344, 612 lesions) or clopidogrel (group 2, n = 345, 628 lesions). The incidence of subacute stent thrombosis or major adverse cardiac events, including death, myocardial infarction, and target lesion revascularization within 30 days (2.6% in group 1 vs 2.0% in group 2, p = 0.61) and side effects that required cessation of study drug (0.6% each) did not differ statistically between groups. These results indicate that cilostazol is as safe and effective as clopidogrel in preventing thrombotic complications after stenting.

UR - http://www.scopus.com/inward/record.url?scp=15244356877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15244356877&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2004.12.012

DO - 10.1016/j.amjcard.2004.12.012

M3 - Article

C2 - 15781016

AN - SCOPUS:15244356877

VL - 95

SP - 859

EP - 862

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 7

ER -